Subscriptions 2017-11-09T11:55:49+00:00

Gain Unlimited Access To Over $10,000 of Journals, Articles and Supplements with a Digital Subscription to Psychopharmacology Bulletin

PSYCHOPHARMACOLOGY BULLETIN (PB) is an academic, peer-reviewed, Index Medicus journal, which accepts no advertising. The journal became MedWorks Media’s flagship publication in 1999. Over nearly 2 decades, Psychopharmacology Bulletin has published hundreds of articles featuring hundreds of topics, drugs and authors. PB relies solely on individual, library and institutional subscriptions. Psychopharmacology Bulletin covers a wide range of categories including:

Original Research – Evidence-Based Medicine – Drug Disposition and Pharmacokinetics – Translational Neuroscience – Complicated Case Histories – Psychopharmacology – Psychopharmacology Research – Pharmaceutical Research – Psychiatric Research – Mental Illness

The purchase of a subscription grants unique access and discounts on the MedWorks Media website:

  • Full Access to the Psychopharmacology Bulletin Subscribers Portal: An easy way to quickly download PDF versions of any article published from 1999 to the present. The portal is a great resource to browse and download multiple files in the shortest amount of time.
  • 100% Discount on All Psychopharmacology Bulletin Articles and Journal Supplements: MedWorks Media recently implemented an advanced search engine to its website, allowing users to search by drug, author or topic. With a Subscription, users are able to search our library for the articles or journal supplements they need, and download them free of charge.

Psychopharmacology Bulletin Digital Subscriptions are an incredible value for individuals, institutions and multiple IP access libraries. Our 2018 subscription prices are as follows:


  • Unlimited access to Psychopharmacology Bulletin Portal for a single doctor


  • Unlimited access to Psychopharmacology Bulletin Portal for a single institution


On Request
  • Unlimited access to the P.B. Portal on multiple IP addresses

Free Article Preview From Latest Issue
Psychopharmacology Bulletin Volume 47 Issue No. 4

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant